Lumida
/FENC
⌘K
Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc

FENC
$10.96USD-3.01%-0.34 today

MARKET CAP

384.3M

P/E (TTM)

FWD P/E

DAY RANGE

$11 – $12

52W RANGE

$6
$13

AI Summary

Stalk
StalkMedium

FENC remains in a high-confidence Stage 2 advancing uptrend with an active momentum breakout confirming medium-term bullish structure, but price is currently extended above rising EMAs with overbought RSI and options score, making short-term execution unfavorable; deferred entries on a healthy pullback into support are advised.

  • Q2 revenue rose 78% YoY to $17.1 M with net income of $1.97 M
  • Non-GAAP EBITDA turned positive at $2.8 M vs a $1.2 M loss prior year
  • Negative earnings yield and low book-to-price suggest overvaluation
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2020FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$170,000$1.5M$21.3M$47.5M$44.6M
YoY %+1284.5%+123.7%-6.1%
P / Sales1038.8x171.7x13.9x3.6x4.9x
EV / Sales874.1x175.4x15.1x4.1x4.9x
Gross Profit, Adj.$170,000$1.4M$20.0M$44.4M$40.9M
YoY %+1279.8%+121.8%-7.8%
Margin %100.0%94.4%94.1%93.3%91.6%
EV / Gross Profit874.1x185.8x16.0x4.4x5.3x
EBITDA, Adj.$-17.9M$-22.6M$-12.8M$2.6M$-6.3M
YoY %-37.5%-31.2%+43.5%+120.1%-344.6%
Margin %-10520.6%-1471.6%-60.1%5.4%-14.1%
EV / EBITDA-8.3x-11.9x-25.1x76.6x-34.8x
EBIT$-17.9M$-22.6M$-12.8M$2.6M$-6.3M
YoY %-37.5%-31.2%+43.5%+120.1%-344.6%
Margin %-10520.6%-1471.6%-60.1%5.4%-14.1%
EV / EBIT-8.3x-11.9x-25.1x76.6x-34.8x
Net Income$-18.1M$-23.7M$-16.0M$-436,000$-9.7M
YoY %-41.8%-36.7%+32.3%+97.3%-2134.2%
Net Margin-10652.4%-1544.9%-75.5%-0.9%-21.8%
EPS (GAAP)-$0.76-$0.90-$0.60-$0.02-$0.34
YoY %-18.8%-34.3%+33.3%+96.7%-1600.0%